Aerosol BCG treatment of carcinoma metastatic to the lung: A phase I study

Fredric B. Garner, Carol A. Meyer, Deborah S. White, Allan Lipton

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

BCG (TICE) was safely administered to 15 patients with metastatic cancer to the lungs in weekly doses of up to 3 × 107 organisms by the aerosol route. The aerosol route of administration is associated in approximately 33% of the doses with a toxicity syndrome of malaise, fever, and chills beginning 4 to 8 hours after treatment and ending within 24–36 hours. This syndrome is experienced by all patients and symptoms gradually subside with continuation of therapy. No hepatic or pulmonary toxicity was documented during the 221 treatment doses.

Original languageEnglish (US)
Pages (from-to)1088-1094
Number of pages7
JournalCancer
Volume35
Issue number4
DOIs
StatePublished - Apr 1975

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Aerosol BCG treatment of carcinoma metastatic to the lung: A phase I study'. Together they form a unique fingerprint.

Cite this